The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes

被引：23

作者：

Stoian, Anca Pantea ^{[1
]}

Sachinidis, Alexandros ^{[2
,3
]}

Stoica, Roxana Adriana ^{[1
]}

Nikolic, Dragana ^{[2
]}

Patti, Angelo Maria ^{[2
]}

Rizvi, Ali A. ^{[4
]}

机构：

[1] Carol Davila Univ Med & Pharm, Dept Diabet Nutr & Metab Dis, Bucharest, Romania

[2] Univ Palermo, PROMISE Dept, Sch Med, Palermo, Italy

[3] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, Sch Med, Thessaloniki, Greece

[4] Emory Univ, Div Endocrinol Metab & Lipids, Sch Med, Atlanta, GA 30322 USA

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 109卷

关键词：

INCRETIN-BASED THERAPIES; MAJOR CARDIOVASCULAR EVENTS; GLUCAGON-LIKE PEPTIDE-1; ADD-ON THERAPY; DPP-4; INHIBITORS; ACUTE-PANCREATITIS; HEART-FAILURE; COMBINATION THERAPY; AMERICAN-COLLEGE; POSITION STATEMENT;

D O I：

10.1016/j.metabol.2020.154295

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: The dipeptidyl peptidase-4 inhibitors (DPP-4is), which belong to the class of incretin-based-medications, are recommended as second or third-line therapies in guidelines for the management of type 2 diabetes mellitus. They have a favorable drug tolerability and safety profile compared to other glucose-lowering agents. Objective: This review discusses data concerning the use of DPP-4is and their cardiovascular profile, and gives an updated comparison with the other oral glucose-lowering medications with regards to safety and efficacy. Currently available original studies, abstracts, reviews articles, systematic reviews and meta-analyses were included in the review. Discussion: DPP4is are moderately efficient in decreasing the HbA1c by an average of 0.5% as monotherapy, and 1.0% in combination therapy with other drugs. They have a good tolerability and safety profile compared to other glucose-lowering drugs. However, there are possible risks pertaining to acute pancreatitis and pancreatic cancer. Conclusion: Cardiovascular outcome trials thus far have proven the cardiovascular safety for ischemic events in patients treated with sitagliptin, saxagliptin, alogliptin, linagliptin and vildagliptin. Data showing increased rate of hospitalisation in the case of saxagliptin did not seem to be a class effect. (C) 2020 Published by Elsevier Inc.

引用

页数：8

共 129 条

[1] Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials [J].

Abbas, A. S. ;

Dehbi, H. -M. ;

Ray, K. K. .

DIABETES OBESITY & METABOLISM, 2016, 18 (03) :295-299

[2] Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer [J].

Abdelmoneim, A. S. ;

Eurich, D. T. ;

Light, P. E. ;

Senior, P. A. ;

Seubert, J. M. ;

Makowsky, M. J. ;

Simpson, S. H. .

DIABETES OBESITY & METABOLISM, 2015, 17 (06) :523-532

[3] Characterization of GLP-1 effects on β-cell function after meal ingestion in humans [J].

Ahrén, B ;

Holst, JJ ;

Mari, A .

DIABETES CARE, 2003, 26 (10) :2860-2864

[4] DPP-4 Inhibition and the Path to Clinical Proof [J].

Ahren, Bo .

FRONTIERS IN ENDOCRINOLOGY, 2019, 10

[5] Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years? [J].

Ahren, Bo .

DIABETOLOGIA, 2015, 58 (08) :1740-1744

[6] 5. Glycemic Targets [J].

不详 .

DIABETES CARE, 2016, 39 :S39-S46

[7] Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020 [J].

不详 .

DIABETES CARE, 2020, 43 :S98-S110

[8] Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats [J].

Aroor, Annayya R. ;

Sowers, James R. ;

Bender, Shawn B. ;

Nistala, Ravi ;

Garro, Mona ;

Mugerfeld, Irina ;

Hayden, Melvin R. ;

Johnson, Megan S. ;

Salam, Muhammad ;

Whaley-Connell, Adam ;

DeMarco, Vincent G. .

ENDOCRINOLOGY, 2013, 154 (07) :2501-2513

[9] Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis [J].

Azoulay, Laurent ;

Filion, Kristian B. ;

Platt, Robert W. ;

Dahl, Matthew ;

Dormuth, Colin R. ;

Clemens, Kristin K. ;

Durand, Madeleine ;

Hu, Nianping ;

Juurlink, David N. ;

Paterson, J. Michael ;

Targownik, Laura E. ;

Turin, Tanvir C. ;

Ernst, Pierre .

JAMA INTERNAL MEDICINE, 2016, 176 (10) :1464-1473

[10] Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes [J].

Bailey, Clifford J. ;

Del Prato, Stefano ;

Wei, Cheryl ;

Reyner, Daniel ;

Saraiva, Gabriela .

DIABETES OBESITY & METABOLISM, 2019, 21 (11) :2564-2569

← 1 2 3 4 5 6 7 8 9 10 →